This presentation focuses on the molecular pathways involved in the development of asbestos-related diseases, emphasising the roles of oxidative stress, DNA repair, and xenobiotic metabolism. It explores how both germline mutations and single-nucleotide polymorphisms (SNPs) within these pathways influence individual susceptibility. By understanding these mechanisms, researchers can identify clinically relevant biomarkers that support early diagnosis and risk assessment.